NASDAQ:HOWL Werewolf Therapeutics Q2 2023 Earnings Report $1.08 -0.06 (-5.26%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.03 -0.05 (-4.17%) As of 07:50 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Werewolf Therapeutics EPS ResultsActual EPS-$0.14Consensus EPS -$0.41Beat/MissBeat by +$0.27One Year Ago EPSN/AWerewolf Therapeutics Revenue ResultsActual Revenue$8.08 millionExpected Revenue$3.05 millionBeat/MissBeat by +$5.03 millionYoY Revenue GrowthN/AWerewolf Therapeutics Announcement DetailsQuarterQ2 2023Date8/10/2023TimeN/AConference Call DateThursday, August 10, 2023Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Werewolf Therapeutics Earnings HeadlinesWerewolf Therapeutics Stock Price, Quotes and ForecastsMay 20 at 10:47 PM | benzinga.comHonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124May 20 at 4:01 PM | globenewswire.comA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing career. In a special event watched by thousands, he unveiled what he calls “the boldest undertaking” he’s ever attempted — a real-money initiative that will document every trade, decision, win, and loss in pursuit of a million-dollar mission. And the results are already surprising. One early beta tester tripled her investment income in just three trades.May 22, 2025 | Porter & Company (Ad)Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development SummitMay 13, 2025 | globenewswire.comWerewolf Therapeutics, Inc.: Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 9, 2025 | finanznachrichten.deWerewolf Therapeutics Announces Q1 2025 Financial ResultsMay 9, 2025 | msn.comSee More Werewolf Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Werewolf Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Werewolf Therapeutics and other key companies, straight to your email. Email Address About Werewolf TherapeuticsWerewolf Therapeutics (NASDAQ:HOWL), a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.View Werewolf Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba's Earnings Just Changed Everything for the StockCisco Stock Eyes New Highs in 2025 on AI, Earnings, UpgradesSymbotic Gets Big Earnings Lift: Is the Stock Investable Again?D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum Holds Upcoming Earnings PDD (5/27/2025)AutoZone (5/27/2025)Bank of Nova Scotia (5/27/2025)NVIDIA (5/28/2025)Synopsys (5/28/2025)Bank of Montreal (5/28/2025)Salesforce (5/28/2025)Costco Wholesale (5/29/2025)Marvell Technology (5/29/2025)Canadian Imperial Bank of Commerce (5/29/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
